France's anti-doping agency today accused Lance Armstrong of violating its rules for not fully cooperating with a drug tester in March and says it could punish the seven-time Tour de France champion. Armstrong has denied misbehaving during a test of his hair, urine and blood on March 17. No banned substances were found.
In a press statement, Merck said that patients taking cladribine tablets had a nearly 60 percent lower relapse rate than those on placebo pills. The two-year study included 1,326 MS patients who were randomly divided into three groups. Two groups received different doses of cladribine and one group received fake pills. Patients on cladribine had up to a 60 percent reduced chance of having a relapse compared to patients on placebo. The study was paid for by Merck.
View your ad here! Cost effective targeted advertising. Contextual advertising starting as low as $79/month. This includes targeted ad delivery and search results! Add your business to the Marketplace »